Fig. 2: RapaBlock protects mTORC1 activity in the liver. | Nature Communications

Fig. 2: RapaBlock protects mTORC1 activity in the liver.

From: Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice

Fig. 2

a Timeline of the experiment. Mice received a systemic administration of vehicle (white), RapaLink-1 alone (1 mg/kg, purple) or a combination of RapaLink-1 (1 mg/kg, purple) and RapaBlock (40 mg/kg, pink), and mTORC1 activity in the liver was measured 3 h later. b, d Representative images depict S6 phosphorylation (pS6) b and 4E-BP phosphorylation (p4E-BP) d (top panels), total protein levels of S6 b and 4E-BP d (middle panels), and actin b, d (bottom panels), which was used as a loading control. c, e Data are presented as the individual data points and mean densitometry values of the phosphorylated protein divided by the densitometry values of the total protein ± SEM and expressed as % of vehicle. Significance was determined using One-way ANOVA followed by Tukey’s multiple comparisons test. RapaBlock protects mTORC1 activity in the liver. pS6 (One-way ANOVA: F2,15 = 20.56, p < 0.0001, r2 = 0.7327; vehicle vs. RapaLink-1 p = 0.0006, vehicle vs. RapaLink-1+RapaBlock p = 0.4796, RapaLink-1 vs. RapaLink-1+RapaBlock p < 0.0001). p4E-BP (one-way ANOVA: F2,15 = 42.77, p < 0.0001, r2 = 0.9101; vehicle vs. RapaLink-1 p < 0.0001, vehicle vs. RapaLink-1+RapaBlock p = 0.0713, RapaLink-1 vs. RapaLink-1+RapaBlock p < 0.0001). n = 6 per condition. ***p < 0.001, ns = non-significant.

Back to article page